Bluejay Diagnostics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bluejay Diagnostics, Inc. (BJDX) on September 8, 2026, reporting events occurring on September 1, 2026. The Company, an emerging growth company incorporated in Delaware, operates in the medical diagnostics sector. The filing primarily addresses the entry into a material definitive agreement to expand distribution channels into the U.S. federal government healthcare market.
Key Financial Metrics and Agreement Terms
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or debt levels for a specific reporting period. Instead, it details the financial structure of a new partnership:
- Establishment Fee: The Company paid a one-time discounted fee of $5,500 for multi-contract vehicle setup.
- Distribution Fees: Lovell Government Services, Inc. ("Lovell") is entitled to an approximate 15% distribution fee on gross sales through federal catalogs. This fee is added to the Company's cost of goods sold and does not reduce the Company's profit margin.
- DAPA Fees: A 2% fee on gross sales applies to sales made through Lovell's catalogs listed with DAPA prime vendors.
- Payment Terms: Lovell must remit full payment within three business days of receiving payment from the government customer or within 30 days of invoice receipt, whichever is later. Undisputed late payments accrue interest at the lesser of 18% per annum or the maximum rate permitted by law.
- Pricing Stability: Prices on Lovell's federal contract catalogs remain fixed for a minimum of 12 months from the original listing date.
Material Changes and Strategic Developments
The primary material change is the execution of a Distribution, Co-Marketing & Strategic Partnership Agreement with Lovell, a Service-Disabled Veteran-Owned Small Business (SDVOSB). Key strategic shifts include:
- Exclusive Rights: Lovell holds the sole and exclusive right to distribute Bluejay's products for federal procurement opportunities requiring or favoring SDVOSB set-aside status (e.g., VA, DoD, IHS).
- Non-Exclusive Rights: Lovell has a non-exclusive right to resell products on open-market (non-set-aside) federal, state, and local government procurements.
- Market Access: The agreement enables distribution through various federal contract vehicles including VA Federal Supply Schedule, GSA Advantage, GSA Multiple Award Schedule, ECAT, and DAPA.
- Co-Marketing: The parties will collaborate on joint marketing plans, conferences, and educational initiatives to raise awareness among federal healthcare stakeholders, contingent upon FDA clearance.
Outlook, Risks, and Contingencies
Outlook and Term: The agreement has an initial term of two years with automatic renewal for successive one-year terms unless terminated with 90 days' notice. The Company may submit up to two price increase requests per calendar year, subject to 90 days' advance notice.
Risks and Termination: Either party may terminate the agreement immediately if the other is suspended, excluded, or sanctioned under healthcare programs, convicted of certain criminal offenses, subject to bankruptcy, or has a final judgment exceeding $100,000 that impairs performance. Termination is also permitted for uncured defaults after 30 days.
Regulatory Contingency: The distribution and co-marketing activities are explicitly conditioned on the Company obtaining applicable FDA clearance or other required regulatory authorization.
Investor Verification Checklist
- Verify the status of FDA clearance or regulatory authorization required to activate the distribution rights.
- Review the full text of the Distribution Agreement (Exhibit 10.1) for specific product exclusions or performance milestones not detailed in the summary.
- Assess the financial impact of the 15% distribution fee on future gross margins for federal sales.
- Confirm Lovell Government Services' current standing and capacity as an SDVOSB distributor.
- Monitor the Company's ability to execute the co-marketing strategy with federal stakeholders (VA, DoD, IHS).